MX2009009020A - Uso de riboflavina en el tratamiento de la hipertension. - Google Patents

Uso de riboflavina en el tratamiento de la hipertension.

Info

Publication number
MX2009009020A
MX2009009020A MX2009009020A MX2009009020A MX2009009020A MX 2009009020 A MX2009009020 A MX 2009009020A MX 2009009020 A MX2009009020 A MX 2009009020A MX 2009009020 A MX2009009020 A MX 2009009020A MX 2009009020 A MX2009009020 A MX 2009009020A
Authority
MX
Mexico
Prior art keywords
riboflavin
treatment
hypertension
provides
subject
Prior art date
Application number
MX2009009020A
Other languages
English (en)
Spanish (es)
Inventor
Mary Ward
Helene Mcnulty
Geraldine Horigan
Sean Strain
John Scott
John Purvis
Original Assignee
Univ Ulster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ulster filed Critical Univ Ulster
Publication of MX2009009020A publication Critical patent/MX2009009020A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009009020A 2007-02-23 2008-02-22 Uso de riboflavina en el tratamiento de la hipertension. MX2009009020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0703514.0A GB0703514D0 (en) 2007-02-23 2007-02-23 Use of riboflavin
PCT/EP2008/001437 WO2008101724A1 (en) 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension

Publications (1)

Publication Number Publication Date
MX2009009020A true MX2009009020A (es) 2010-02-17

Family

ID=37945596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009020A MX2009009020A (es) 2007-02-23 2008-02-22 Uso de riboflavina en el tratamiento de la hipertension.

Country Status (10)

Country Link
US (1) US20100324019A1 (enExample)
EP (1) EP2139488B1 (enExample)
JP (1) JP5577100B2 (enExample)
CN (1) CN101678030B (enExample)
CA (1) CA2679217C (enExample)
EA (1) EA019281B1 (enExample)
ES (1) ES2393144T3 (enExample)
GB (1) GB0703514D0 (enExample)
MX (1) MX2009009020A (enExample)
WO (1) WO2008101724A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104737023B (zh) * 2012-08-16 2017-07-28 重症监护诊断股份有限公司 预测患高血压风险的方法
CN103721259A (zh) * 2014-01-07 2014-04-16 深圳奥萨医药有限公司 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物
CN109295216A (zh) * 2018-11-06 2019-02-01 宁波艾捷康宁生物科技有限公司 预测高血压个体化药物药效的snp位点和检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
DE3682208D1 (de) * 1986-12-18 1991-11-28 Kurt Heinz Bauer Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
US6485959B1 (en) * 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
CN1136895C (zh) * 2001-05-24 2004-02-04 魏振鸣 一种治疗冠心病的药物
WO2006085128A1 (en) * 2005-02-09 2006-08-17 Wockhardt Limited Cardiovascular therapeutic combinations
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders

Also Published As

Publication number Publication date
US20100324019A1 (en) 2010-12-23
CA2679217A1 (en) 2008-08-28
EP2139488A1 (en) 2010-01-06
EA019281B1 (ru) 2014-02-28
GB0703514D0 (en) 2007-04-04
CN101678030B (zh) 2013-06-05
EP2139488B1 (en) 2012-08-15
CN101678030A (zh) 2010-03-24
WO2008101724A1 (en) 2008-08-28
EA200901145A1 (ru) 2010-02-26
JP2010519235A (ja) 2010-06-03
WO2008101724A8 (en) 2009-10-08
CA2679217C (en) 2016-05-17
JP5577100B2 (ja) 2014-08-20
ES2393144T3 (es) 2012-12-18

Similar Documents

Publication Publication Date Title
WO2007146426A3 (en) Nanoshells for drug delivery
CA2963423A1 (en) Device and method for delivery of a medicament
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2009105432A3 (en) Devices and methods for delivery of a therapeutic agent through a pneumostoma
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
WO2010045417A3 (en) Combination therapies for the treatment of obesity
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO2010151503A3 (en) Combination therapies for the treatment of obesity
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW200642704A (en) Oral drug delivery system and methods of use thereof
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
GB2446341A (en) Method and system for transdermal drug delivery
MX2009009020A (es) Uso de riboflavina en el tratamiento de la hipertension.
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights